REHOVOT, Israel, Sept. 18, 2023 /PRNewswire/ -- CardiaCare, a medical device company developing a breakthrough wearable technology for detecting, monitoring, and non-invasively treating cardiac arrhythmias using drug-free neuromodulation, recently closed an over-subscribed Seed Extension round. The financing was led by Solardis Health Ventures and supports efforts to expand the technology's clinical program for multiple indications related to treating Atrial Fibrillation (AFib). CardiaCare's platform can simultaneously help physicians remotely monitor their patients and create dynamic, personalized neuromodulation treatments based on the real-time patient's condition data. CardiaCare's mission is to become the new standard of care all-in-one therapeutic monitoring platform for cardiac arrhythmia patients across the continuum of care.

"The oversubscribed closure of this round is a reflection of the potential of CardiaCare's technology to disrupt the standard of care for AFib. We are proud to have Solardis Health Ventures along with savvy clinical and commercial leaders support our journey. The funds will be used to support existing and future double-blind, multicenter clinical studies to demonstrate the clinical efficacy of CardiaCare's therapy for various indications" said Ofer Halbreich, CEO.

"CardiaCare's innovative solution has the potential to significantly disrupt the standard of care in the treatment of AFib and other arrhythmias with a non-invasive wearable that administers neuromodulation stimulation therapy. Multiple clinical studies are already under way as we push to bring this advancement in cardiac care to market," said Ken Nelson, Chairman.

"CardiaCare's novel approach to treating AFib using neuromodulation will be a paradigm shift for the millions of patients that have no alternatives to toxic drugs, cardioversion shock therapy, or invasive procedures. Solardis Health Ventures is proud to lead this round and support CardiaCare's mission to become the first therapeutic wearable for cardiac arrhythmia patients," added Amir Soltanianzadeh, Founder & Managing Partner of Solardis Health Ventures.

About CardiaCare

CardiaCare is a privately-held, Israel-based company developing a platform for both treating and monitoring cardiac arrhythmias such as Atrial Fibrillation. The venture was founded by cardiac arrhythmia specialist and entrepreneur, Amos Ziv, after over a decade of caring for and creating new therapies for patients with AFib. Website: https://my-CardiaCare.com

Logo -

Media Contact:

Ofer Halbreich
CEO, CardiaCare
Email: Ofer@my-CardiaCare.com

View original content:https://www.prnewswire.co.uk/news-releases/cardiacare-completes-seed-extension-raise-to-support-clinical-pilot-studies-301927954.html

Images

Tags

More Like This

Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

INHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC, PREDICTIVE, AND SCREENING CARDIAC SOLUTIONS

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

Field Medical, Inc. Announces Oversubscribed Seed Round to Advance Next-Generation Cardiac Ablation Technology

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial